Form 4: CRISPR Therapeutics CMO Repays Short-Swing Profit

CRISPR Therapeutics' Chief Medical Officer, Naimish Patel, has agreed to repay $4,493.84 in short-swing profits from recent share transactions.

Summary

• Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG, reported a purchase of 1,508 common shares on April 3, 2025, at a price of $32.96 per share.
• This purchase was deemed matchable under Section 16(b) of the Securities Exchange Act of 1934 with a subsequent sale of 1,508 common shares on May 29, 2025, at $35.94 per share.
• The subsequent sale was a mandatory 'sell to cover' provision related to a restricted stock unit award that vested on May 29, 2025.
• Mr. Patel has agreed to pay the Issuer $4,493.84, representing the full amount of the profit realized from this short-swing transaction.

Sentiment

Score: 4

Explanation: The filing details a compliance issue (short-swing profit) by a key executive, requiring repayment. While the amount is small relative to the company's size, it reflects a minor negative in terms of executive compliance oversight.

Negatives

• The reporting person, Naimish Patel, realized a short-swing profit of $4,493.84, which is subject to disgorgement under Section 16(b) of the Securities Exchange Act of 1934.
• The need for a profit repayment indicates a compliance oversight regarding insider trading rules for the Chief Medical Officer.

Risks

• Compliance risk for company executives regarding Section 16(b) short-swing profit rules, which can lead to mandatory profit disgorgement.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Naimish Patel has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.

Industry Context

This insider transaction report is specific to an individual executive's share dealings and compliance with SEC rules, and does not directly relate to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct financial impact due to the small amount of profit disgorgement, but it highlights the importance of executive compliance with insider trading regulations.
• Reporting Person (Naimish Patel): Directly impacted by the requirement to repay the realized profit.

Next Steps

• Naimish Patel is obligated to pay $4,493.84 to CRISPR Therapeutics AG to disgorge the short-swing profit.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Naimish Patel, Chief Medical Officer, Short-Swing Profit, Section 16(b), Beneficial Ownership